A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

NCT00431873 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG: MGCD0103

Sponsor

Mirati Therapeutics Inc.